Gene expression polymorphisms of interleukins-1β, -4, -6, -8, -10, and tumor necrosis factors-α, -β: regression analysis of their effect upon oral squamous cell carcinoma

PurposeFunctional DNA polymorphisms affecting gene expression and serum or saliva levels of interleukins IL-1β,-4,-6,-8,-10 and tumor necrosis factors TNF-α,-β have been associated with increased risk for the development of oral squamous cell carcinoma (OSCC). The present retrospective case–control study examines possible interactions between seven cytokine genotype polymorphisms and their combinatory effect in predicting the occurrence of OSCC in Caucasians.MethodsThree hundred and thirty Greeks and Germans were studied, consisting of 162 OSCC cases and 168 healthy controls of comparable age, gender, and ethnicity. A series of multivariate logistic regression models, adjusted for age and gender, was constructed in order to assess the contribution of homozygous or heterozygous variant genotypes of polymorphisms IL-1β (+3953C/T), IL-4 (-590C/T), IL-6 (-174G/C), IL-8 (-251A/T), IL-10 (-1082A/G), TNF-α (-308G/A) and TNF-β (+252G/A) upon overall, early and advanced stages of OSCC development.ResultsThe contribution of TNF-α and IL-6 was consistent and robust in almost all models constructed. Furthermore, when the mode of inheritance of each variant allele was taken into account in a “biological” multivariate logistic regression model, four polymorphisms emerged as primary predictors for overall stages of OSCC: TNF-α (OR = 15.27; 95% CI = 7.30–31.96), IL-6 (OR = 8.33; 95% CI = 3.95–17.58), IL-8 (OR = 3.54; 95% CI = 1.69–7.43) and IL-10 (OR = 2.65; 95% CI = 1.28–5.46). Finally, IL-1β, IL-4 and TNF-β polymorphisms were not primary predictors of OSCC development in all constructed models.ConclusionsThis study revealed the highly significant contributions of two out of seven studied cytokines (IL-6 and TNF-α) in the occurrence of OSCC. Based on these findings and previous reports, possible stoichiometrical interactions of cytokines leading to OSCC development are discussed.

[1]  C. Gassner,et al.  Interleukin-4 Promoter Polymorphisms: A Genetic Prognostic Factor for Survival in Metastatic Renal Cell Carcinoma , 2007 .

[2]  M. Watson,et al.  Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. , 2003, Cancer letters.

[3]  J. Johnson,et al.  Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  F. Lejeune.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. , 2002, The Journal of clinical investigation.

[5]  T. Shono,et al.  Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis , 1997, Molecular and cellular biology.

[6]  F. Tsai,et al.  Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. , 2005, Oral oncology.

[7]  Craig S. Miller,et al.  NF-κB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma , 2005 .

[8]  E. Vairaktaris,et al.  The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  T. Del Beato,et al.  Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer. , 2002, Cancer biotherapy & radiopharmaceuticals.

[10]  E. Nkenke,et al.  The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. , 2008, Anticancer research.

[11]  R Kreutz,et al.  A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. , 1995, The New England journal of medicine.

[12]  T. Day,et al.  Oral Cancer and Precancerous Lesions , 2002, CA: a cancer journal for clinicians.

[13]  Kazuhiro Yoshida,et al.  A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[14]  E. Vairaktaris,et al.  Are factor V and prothrombin mutations associated with increased risk of oral cancer? , 2005, Anticancer research.

[15]  C. Dinarello,et al.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. , 1990, Blood.

[16]  Jason H. Moore,et al.  The Interaction of Four Genes in the Inflammation Pathway Significantly Predicts Prostate Cancer Risk , 2005, Cancer Epidemiology Biomarkers & Prevention.

[17]  K. Chang,et al.  Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[18]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[19]  Q. Wei,et al.  Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. , 2001, Cancer research.

[20]  M. Spitz,et al.  Thymidylate Synthase 5′- and 3′-Untranslated Region Polymorphisms Associated with Risk and Progression of Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.

[21]  Artur Ferreira,et al.  Oral squamous cell carcinoma: review of prognostic and predictive factors. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[22]  F. Gianfagna,et al.  A case–control study investigating the role of sulfotransferase 1A1 polymorphism in head and neck cancer , 2006, Journal of Cancer Research and Clinical Oncology.

[23]  E. Nkenke,et al.  The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer , 2007, Journal of Cancer Research and Clinical Oncology.

[24]  G. Matullo,et al.  Interleukin-1 Gene Polymorphisms and Gastric Cancer Risk in a High-Risk Italian Population , 2005, The American Journal of Gastroenterology.

[25]  E. Jabłońska,et al.  Serum Levels of IL-lβ, IL-6, TNF-α, sTNF-RI and CRP in Patients with oral cavity cancer , 2008, Pathology & Oncology Research.

[26]  S. Chanock,et al.  Polymorphisms in interleukin -2, -6, and -10 are not associated with gastric cardia or esophageal cancer in a high-risk chinese population. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  J. Blay,et al.  Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. , 1996, Cancer research.

[28]  B. Tai,et al.  RNASEL Gene Polymorphisms and the Risk of Prostate Cancer: a Meta-analysis , 2006, Clinical Cancer Research.

[29]  M. Giacovazzo,et al.  Tumor Necrosis Factor Gene Polymorphism in Migraine , 2002, Headache.

[30]  S. Wingren,et al.  Polymorphism in the manganese superoxide dismutase (MnSOD) gene and risk of breast cancer in young women , 2005, Journal of Cancer Research and Clinical Oncology.

[31]  F. Garrido,et al.  High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. , 2007, Human immunology.

[32]  F. Tsai,et al.  Interleukin‐4 gene, but not the interleukin‐1 beta gene polymorphism, is associated with oral cancer , 2005, Journal of clinical laboratory analysis.

[33]  Craig S. Miller,et al.  NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. , 2005, Cancer detection and prevention.

[34]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[35]  K. Hemminki,et al.  Vascular Endothelial Growth Factor Polymorphisms in Relation to Breast Cancer Development and Prognosis , 2005, Clinical Cancer Research.

[36]  B. Mazières,et al.  Interleukin‐1β, interleukin‐1 receptor antagonist, interleukin‐4, and interleukin‐10 gene polymorphisms: Relationship to occurrence and severity of rheumatoid arthritis , 1999 .

[37]  R. Eeles,et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. , 2002, Cancer research.

[38]  E. Nkenke,et al.  Strong Association of Interleukin-6 -174 G>C Promoter Polymorphism with Increased Risk of Oral Cancer , 2006 .

[39]  I. Springer,et al.  Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. , 2006, Oral oncology.

[40]  S. Fujieda,et al.  IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. , 1999, Cancer letters.

[41]  T. Hansen,et al.  The -238 and -308 G-->A polymorphisms of the tumor necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. , 2000, The Journal of clinical endocrinology and metabolism.

[42]  E. Vairaktaris,et al.  Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer , 2006, Journal of Cancer Research and Clinical Oncology.

[43]  Zhaolan Liu,et al.  Joint effects of eNOS gene T-786C and ADH2 Arg47His polymorphisms on the risk of premature coronary artery disease. , 2007, Thrombosis research.

[44]  E. Nkenke,et al.  The interleukin-1 beta gene polymorphism +3953 C/T is not associated with risk for oral cancer. , 2007, Anticancer research.

[45]  U. Spengler,et al.  Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF- beta production , 1991, The Journal of experimental medicine.

[46]  J. Vuopio‐Varkila,et al.  Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria , 1996, Infection and immunity.

[47]  H. K. Williams.  Molecular pathogenesis of oral squamous carcinoma , 2000, Molecular pathology : MP.

[48]  H. Watanabe,et al.  Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. , 2002, Oral oncology.

[49]  J. Wiltfang,et al.  Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[50]  Carlo Montemagno,et al.  Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. , 2004, Archives of otolaryngology--head & neck surgery.

[51]  E. Nkenke,et al.  Strong association of interleukin-4 (-590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. , 2007, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.